Bringing Science to Fertility Care: driving innovation with Fertibiome training & launch

In 2024, Zinereo Pharma and Cigalah Medpharm signed an exclusive agreement for the distribution of Fertibiome and Flowbiotic in the Middle East. As part of the preparation for the official launch, scheduled for October 2025, we conducted an in-depth training session with the Cigalah Medpharm team, focusing on the role of Fertibiome in enhancing fertility outcomes for couples undergoing reproductive treatments.

Beyond the training, we engaged in strategic discussions with leading fertility specialists across the region, reinforcing our commitment to scientific education and international expansion. Our collaboration with Cigalah Medpharm, a premier pharmaceutical and healthcare distribution company in the Middle East, strengthens Zinereo Pharma’s presence in a rapidly growing market that demands cutting-edge probiotic fertility solutions.

At Zinereo Pharma, we are dedicated to innovation, scientific excellence, and global accessibility, ensuring that our solutions remain at the forefront of evidence-based reproductive health advancements.